Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.

Neurooncol Adv · 2022 · PMC9270729 · PMID 35821680

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

9 EGFR wild-type tumors showed a trend for higher PFS with TTFields therapy 17.2 vs 12.6 months for tumors that harbored any alterations even though this finding was not statistically significant (HR = 0.517, P = .3628).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.